What is Ostarine?
Ostarine, also known as Enobosarm or MK-2866, is a Selective Androgen Receptor Modulator (SARM) developed by Gtx inc. Researchers have found that it has the potential to help treat muscle breakdown and osteoporosis.
Also, they found that it can dramatically increase muscle mass without the side effects of real steroids. That’s why bodybuilders today use it to build muscle and improve performance.
What do you expect from it?
Now, let’s take a look at some of the benefits.
- Build muscle mass
- Better bone health
- Also, boost heart health
- Reduce blood sugar and lipids
- Weight loss
- Wound healing
- Avoid injury
PCT
To minimize estrogen and the short and long-term harmful effects on testosterone, most bodybuilders start PCT immediately after a course of ostarine. PCT (post cycle therapy) consists of antiestrogens (such as Clomid, Nolvadex), usually taken for 3-4 weeks.
Also, users who are more sensitive to estrogen or those taking high doses can combine it with aromatase inhibitors (Arimidex), which inhibit androgens’ conversion estrogen.
In general, opinions are divided on the PCT. Some people do not need to take it after Ostarine, especially at lower doses (around 10 mg/day). Others believe that you should take both antiestrogens and aromatase inhibitors after courses of it. Users who monitor their lab and see an increase in estrogen levels start with aromatase inhibitors.
Dosage:
For body building:
- Men: 25 mg/day
- Women:10 mg/day
For Cutting:
- Men: 15 – 20 mg/day
- Women: N/A
For body recomposition:
- 12.5-25mg/day
Ostarine Bulking & Cutting Stacks
MK-2866 is a phenomenal bulking SARM and is often stacked with other SARMs
Bulking Stack | Cutting Stack |
Ostarine– 10-25 mg per day | Ostarine – 15-20 mg per day |
RAD-140– 10 mg per day | Cardarine– 10-20 mg per day |
YK11– 5 mg per day | Andarine– 15-20mg per day |
At last, Roidfactory always takes care of its clients. We will also ensure the quality of the products. So, buy Ostarine from us and turn your luck today!
Reviews
There are no reviews yet.